US EditionNovo Nordisk ends deal with Hims & Hers over sales of Wegovy copycats; HIMS drops 20%
- On June 23, 2025, Novo Nordisk announced that it would discontinue its partnership with Hims & Hers Health following concerns over the telehealth company's promotion and sale of unauthorized, lower-cost versions of Wegovy.
- The partnership was terminated after Novo Nordisk accused Hims & Hers of unlawfully distributing large quantities of compounded drugs while misleadingly presenting them as customized treatments.
- Novo Nordisk stated these knock-offs contain semaglutide ingredients from uninspected Chinese suppliers, posing patient safety risks while it continues to provide authentic Wegovy via trusted telehealth partners.
- Hims & Hers' stock declined roughly 20% before the market opened following the announcement, after having climbed over 150% earlier in 2025 due to impressive revenue increases and a growing number of customers.
- The termination signals caution for investors but Hims may still grow through alternative routes, while Novo Nordisk commits to safeguarding patients with FDA-approved obesity treatments.
128 Articles
128 Articles
HIMS & HERS HEALTH INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick ...
NEW YORK and NEW ORLEANS, June 24, 2025 (GLOBE NEWSWIRE) -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), is investigating claims on behalf of…
HIMS & HERS HEALTH INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates Claims on Behalf of Investors of Hims & Hers Health, Inc. - HIMS - Hims & Hers Health (NYSE:HIMS)
NEW YORK and NEW ORLEANS, June 24, 2025 (GLOBE NEWSWIRE) -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), is investigating claims on behalf of investors of Hims & Hers Health, Inc. ("Hims" or the "Company") (NYSE:HIMS). The investigation concerns whether Hims & Hers Health and certain of its officers and/or directors have engaged in fraud, negligence or other unlawf…
The Conway Daily Sun
Berger Montague Investigates Potential Securities Class Action Against Hims & Hers Health, Inc.
PHILADELPHIA, June 24, 2025 /PRNewswire/ -- Berger Montague, a nationally recognized securities litigation firm, is investigating potential claims on behalf of investors who purchased or otherwise acquired securities of Hims & Hers Health, Inc. ("Hims & Hers" or the "Company")…
The recent break between Hims & Hers and Novo Nordisk led to a 35% sharp fall in Hims & Hers shares.According to the original report, Novo Nordisk, the Danish pharmaceutical giant, decided to terminate his agreement because Hims promoted a more economical version of his popular weight loss drug, Wegovy.Accusations and ControversiesThe situation escalated quickly after Novo Nordisk accused Hims of violating laws by selling massively composite dru…
Coverage Details
Bias Distribution
- 62% of the sources are Center
To view factuality data please Upgrade to Premium
